To ensure the safe use of valproate-containing medicines in the treatment of epilepsy and bipolar disorder in the UK, the Medicines and Healthcare products Regulatory Agency has changed the licences of the drugs so that they cannot be prescribed to women or girls of childbearing potential unless they are on a pregnancy prevention program (PPP).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?